Nortriptyline for pain in knee osteoarthritis: a double-blind randomised controlled trial in New Zealand general practice | British Journal of General Practice

Intended for Healthcare Professionals

Intended for Healthcare Professionals

Published eLetters

eLetter submission guidelines

Submit a Response to This Article

Compose eLetter

Title *

Author Information

Contributors

First Name and Middle Initial *

First or given name, e.g. 'Peter'.

Last Name *

Your last, or family, name, e.g. 'MacMoody'.

Email Address *

Your email address, e.g. higgs-boson@gmail.com. PLEASE NOTE: your email address will be published.

Occupation *

Your role and/or occupation, e.g. 'Orthopedic Surgeon'.

Affiliation *

Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

No

Please describe the competing interests

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Jump to comment:

Result of primary outcome
Shu Yun Tan

Published on: 24 November 2022

Published on: (24 November 2022)
Page navigation anchor for Result of primary outcome
Result of primary outcome
Shu Yun Tan, GP, National Healthcare Group Polyclinics Singapore
Dear Authors

I am writing to clarify about the primary outcome reported in the study.

Efficacy (e541)
Primary Outcome: On average, participants were given nortriptyline had a WOMAC pain subscale score at week 14 that was 6.2 points lower (95% CI = -0.26 to 12.56)

May I ask if the 95% CI reported is corrected as the score of -6.2 is not within the 95% CI.

Competing Interests: None declared.

In this issue

Download PowerPoint

Keywords

More in this TOC Section

Show more Research

Related Articles

Cited By...

Intended for Healthcare Professionals

@BJGPjournal's Likes on Twitter